Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Bath emollient for infants up to the age of one as per NICE guidance

Generic rivaroxaban (once daily) and generic apixaban (twice daily) are joint best-value DOACS for patients commencing treatment for atrial fibrillation

Generic rivaroxaban (once daily) and generic apixaban (twice daily) are joint best-value DOACS for patients commencing treatment for atrial fibrillation

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

Safety lancets are considerably more expensive than standard lancets; they should only be prescribed for patients who are unable to self-test and require assistance from a healthcare worker to obtain a blood sample. They should not be prescribed for patients who self-test.

High dose ICS for asthma only - please take advice from secondary care.

Lubiprostone course of treatment for constipation is 2 weeks. See NICE guidance for advice on when it may be considered.

Jaydess (levonorgestrel) Intrauterine system is accepted as a third line option for women requesting long acting reversible contraception when an implant is unacceptable or unsuitable and a Mirena fitting has been or is likely to be unsuccessful. Jaydess provides 3 years of contraceptive cover compared to 5 years for Mirena.

Kyleena is accepted onto the formulary where Mirena may not be appropriate

Potent

Should be used only by doctors with anaesthetic training and should not be administered parenterally unless resuscitation equipment is available

Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate (Jan 2024 DSU)

Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate (Jan 2024 DSU)

Potent

Monopost eye drops (latanoprost unit dose vials) are accepted for use in patients who have proven sensitivity to the preservative benzalkonium chloride and should be used in preference to tafluprost. Monopost is substantially more expensive than the equivalent generic multi-dose eye drop preparation with preservative.

Should be used only by doctors with anaesthetic training and should not be administered parenterally unless resuscitation equipment is available

Administered OD or BD

Accepted for use in line with NICE TA 1009

Lacosamide contains soya and peanut oil and should not be given to patients with an allergy to either of these components.

If patients have not experienced improvement in their symptoms after 4 weeks of treatment, the patient should be re-examined and the benefit and risks of continuing treatment reconsidered.

Lacosamide contains soya and peanut oil and should not be given to patients with an allergy to either of these components.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Only to be prescribed for existing patients. No new patient initiations.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lidocaine 5% medicated plasters (Grunenthal Ltd) is the new name for “Ralvo” Prescribing note: Please prescribe as Lidocaine 5% medicated plasters (Grunenthal Ltd) for cost-effective choice

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lacosamide contains soya and peanut oil and should not be given to patients with an allergy to either of these components.

Lacosamide contains soya and peanut oil and should not be given to patients with an allergy to either of these components.

Lacosamide contains soya and peanut oil and should not be given to patients with an allergy to either of these components.

Please be advised that this should only be prescribed through the IVF clinics and not via primary care

To be prescribed via specialist weight management service only

1. Linezolid should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist. In exceptional circumstances it may be considered appropriate for a GP to commence treatment in a primary care setting (off-license use), only under the recommendation and supervision of a microbiologist. This should be discussed on an individual patient basis.

For use in line with NICE TA958